You are here: Industry Insights > Otonomy

News List

OTIVIDEX Trial for Ménière’s Disease Does Not Meet Primary Endpoint americanpharmaceuticalreview
February 25, 2021
Otonomy announced the Phase 3 clinical trial of OTIVIDEX in patients with Ménière’s disease did not achieve the primary endpoint, which was the count of definitive vertigo days (DVD) in Month 3 for OTIVIDEX vs. placebo for the intent-to-treat (ITT) ...
Otonomy Reports Positive Top-Line Results from OTO-413 Trial for Hearing Loss americanpharmaceuticalreview
January 06, 2021
Otonomy announced positive top-line results from the Phase 1/2 clinical trial of OTO-413 in subjects with speech-in-noise hearing difficulty.
Otonomy Reports Positive Top-Line Results from OTO-313 Trial for Tinnitus americanpharmaceuticalreview
July 16, 2020
Otonomy announced positive top-line results from the Phase 1/2 clinical trial of OTO-313 in patients with persistent tinnitus of at least moderate severity.
Otonomy’s renaissance starts as Ménière’s disease drug clears trial fiercebiotech
November 10, 2017
Just weeks after a phase 3 setback caused it to slash staff and R&D programs, Otonomy has bounced back with a positive late-stage trial for its lead candidate Otividex in Ménière’s disease.
Otonomy’s renaissance starts as Ménière’s disease drug clears trial fiercebiotech
November 10, 2017
Just weeks after a phase 3 setback caused it to slash staff and R&D programs, Otonomy has bounced back with a positive late-stage trial for its lead candidate Otividex in Ménière’s disease.